DCIS patients receiving anastrozole reported symptoms different from those receiving tamoxifen

(American Association for Cancer Research) Analysis of patient-reported outcomes (PRO), a secondary endpoint of the phase III, NSABP B-35 clinical trial, in which anastrazole and tamoxifen were compared in postmenopausal women with ductal carcinoma in-situ (DCIS) who underwent lumpectomy plus radiotherapy, found that there were no differences in outcomes related to quality of life but some differences in outcomes related to symptoms in the two treatment groups, according to data presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Abstract We aimed to evaluate the surgical margin outcomes and re-excision rates in patients undergoing bracketed seed localization of biopsy-proven breast cancer detected on screening mammogram. After approval by our Institutional Review Board, we retrospectively identified patients who had undergone iodine-125 seed localized lumpectomy at our institution from January 2010 to June 2017 by one of two fellowship-trained breast surgeons. Of those patients, a subset of 25 patients were identified who had undergone bracketed seed localization, defined as two or more seeds used to delineate the radiographic borders of ...
Source: The American Surgeon - Category: Surgery Authors: Tags: Am Surg Source Type: research
Conclusion: The findings of this study are comparable to results in the literature on OPS and demonstrate that OPS is an attractive alternative to standard lumpectomy for Canadian general surgeons who treat breast cancer. PMID: 31995336 [PubMed - indexed for MEDLINE]
Source: Canadian Journal of Surgery - Category: Surgery Authors: Tags: Can J Surg Source Type: research
ConclusionsA novel system using supine MRI images co-registered with intraoperative optical scanning and tracking enabled tumors to be resected with a trend toward a lower positive margin rate compared with wire-localized partial mastectomy. Margin positivity was more likely when imaging underestimated pathologic tumor size.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Approximately 60,000 women in the United States are diagnosed with ductal carcinoma in situ (DCIS) annually.1 Although DCIS is both a precursor and risk factor for development of invasive breast cancer (IBC), survival after treatment of DCIS is very high regardless of treatment approach.2 After lumpectomy, radiation therapy (RT) decreases local recurrence rates by 50% relatively but has no apparent impact on distant metastases or survival.2 Breast preservation and prevention of local recurrence, either in the form of DCIS or invasive cancer, is thus the primary oncologic benefit of RT in patients who received a diagnosis of DCIS.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Feature Source Type: research
AbstractPurpose of ReviewDuctal carcinoma in situ (DCIS; intraductal carcinoma) of the breast is commonly found in an asymptomatic woman on routine screening mammography. The purpose of this review is to describe current approaches to the management of DCIS as well as areas for future investigation.Recent FindingsRandomized trials have demonstrated that adding radiation treatment after breast conservation surgery (lumpectomy; surgical excision) reduces the rate of ipsilateral local recurrence by about half, and that adding hormonal therapy reduces the rate of all breast cancer events (ipsilateral plus contralateral). Early...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
ConclusionThe HF schedule with CB in DCIS patients is well tolerated and associated with excellent clinical outcomes. This schedule affords the benefit of delivering higher dose to the lumpectomy site without protracting overall treatment time.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
AbstractTertiary oncology center clinicians are commonly faced with the problem of managing patients with a diagnosis of breast cancer made after lumpectomy in the Primary Health Care (PHC) setting. There are no studies or guidelines that address the further surgical management in this group of patients regarding sentinel lymph node biopsy (SLNB) and need for breast post-operative cavity excision. Prospective observational study was planned to evaluate the feasibility of SLNB and defining the need for definitive breast surgery in patients diagnosed with breast cancer after lumpectomy in PHC. The study was carried out from ...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
AbstractTreatment for ductal carcinoma in-situ (DCIS) has historically been extrapolated from studies of invasive breast cancer. Accepted local therapy approaches range from small local excisions, with or without radiation, to bilateral mastectomies. Systemic treatment with endocrine therapy is often recommended for hormone positive patients. With improvements in imaging, pathologic review, and treatment techniques in the modern era, combined with new information regarding tumor biology, the management of DCIS is rapidly evolving. A multidisciplinary approach to treatment is now more important than ever, with a shift towar...
Source: Journal of Mammary Gland Biology and Neoplasia - Category: Cancer & Oncology Source Type: research
MONDAY, Aug. 20, 2018 -- Treatment with lumpectomy and radiotherapy is associated with a reduction in breast cancer mortality versus lumpectomy or mastectomy alone among patients with ductal carcinoma in situ (DCIS), according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
From time to time I have commented on the controversies over cancer screening. Most people assume that screening is an unqualified good, that early detection of cancer saves lives. Whenever some panel proposes recommending less screening, we hear screaming and yelling from advocates who claim they are trying to " ration " health care to save money at the expense of people's lives.In fact,as a bunch of Australians and a Minnesotan explain in BMJ, there are a few conditions called " cancer " that you are better off not treating, or perhaps treating very conservatively. These include what is called ductal ...
Source: Stayin' Alive - Category: American Health Source Type: blogs
More News: Arimidex | Breast Cancer | Breast Carcinoma | Breast Lumpectomy | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | Clinical Trials | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Lumpectomy | Tamoxifen | Women